天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Welcome to chemicalbook!
+1 (818) 612-2111
Inquriy
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >Adropin (34-76) (human, mouse, rat)
Adropin (34-76) (human, mouse, rat)
  • Adropin (34-76) (human, mouse, rat)

Adropin (34-76) (human, mouse, rat) NEW

Price $127 $397 $579
Package 1mg 5mg 10mg
Min. Order:
Supply Ability: 10g
Update Time: 2024-11-01

Product Details

Product Name: Adropin (34-76) (human, mouse, rat) CAS No.: 1802086-30-1
Purity: 99.95% Supply Ability: 10g
Release date: 2024/11/01

Product Introduction

Bioactivity

名稱Adropin (34-76) (human, mouse, rat)
描述Adropin (34-76) (human, mouse, rat) is a peptide that attenuates liver fibrosis and insulin resistance independent of obesity or food intake.
體外活性Method: HUVECs cells were treated with 10 ng/mL Adropin for 18 hours, and then Adropin was added to the culture medium; in addition, HUVECs cell line proteins were isolated, and Adropin (10 ng/mL) was added to the culture medium to stimulate for 0 to 60 minutes to lyse the treated HUVECs. The samples were used to measure phosphorylated ENOs, phosphorylated AKT, and phosphorylated ERK1/2. RESULTS Adropin-treated HUVECs cells showed greater proliferation, migration, and capillary-like tube formation; Adropin upregulated endothelial NO synthase expression through the VEGFR2 2-PI3K-Akt and VEGFR2-extracellular signal-regulated kinase pathways to reduce inflammation. [3] Method: Treat 3T3-L1 cells or rat primary preadipocytes with Adropin (1 - 100 nmol/l) for 24 or 48 hours. After that, add BrdU solution (10μmol/l), incubate the cells for 3 hours, and use Cell Proliferation BrdU Elisa Kit (Roche Diagnostics, Penzberg, Germany) evaluates the binding of BrdU to DNA. RESULTS Adropin (100 nmol/l) stimulated the proliferation of 3T3-L1 preadipocytes after 24 and 48 hours. Adpin at a concentration of 100 nmol/l increased the proliferation of rat preadipocytes after 48 hours; in addition, Adropin stimulated the proliferation of rat preadipocytes through ERK1 /2 and AKT-dependent mechanisms promote 3T3-L1 cell proliferation. [4]
體內(nèi)活性METHODS: DIO C57BL/6 mice maintained on a 60% kcal fat diet received five intraperitoneal (ip) injections of adropin (450 nmol/kg). After treatment, assess glucose tolerance and systemic insulin sensitivity. RESULTS Adropin treatment improved glucose tolerance, enhanced insulin action, and enhanced metabolic flexibility in glucose utilization in mice. [1] METHODS: C57Bl/6 mice were injected with secretable form of Adropin (450 nmol/kg, ip) three times within 24 hours, then fasted, and the hearts were isolated and perfused. RESULTS Adropin administration improved cardiac function, cardiac efficiency, and coronary blood flow compared with untreated mice. [2]
存儲(chǔ)條件store at low temperature,keep away from moisture | Shipping with blue ice.

Company Profile Introduction

Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.

Recommended supplier

Product name Price   Suppliers Update time
$228.00/1mg
VIP3Y
TargetMol Chemicals Inc.
2024-11-19
$0.00/50mg
VIP1Y
TargetMol Chemicals Inc.
2024-10-28
$0.00/10mg
VIP3Y
Wuhan Senwayer Century Chemical Co.,Ltd
2023-06-09
  • Since: 2011-01-07
  • Address: 36?Washington?Street, Wellesley?Hills
INQUIRY